

Special Issue

Emerging Therapies and Strategies in Thalassemia: Toward a New Era in Management—2nd Edition

Message from the Guest Editors

Looking at the pathophysiological mechanisms of beta-thalassemia, new drugs able to ameliorate globin synthesis, reducing ineffective erythropoiesis, chain imbalance, and iron overload, have been undergoing testing for a few years now. Furthermore, considering standard treatments, there is still the need to provide more strength of scientific evidence with long-term prospective observations or, if possible, with randomized trials. Similarly, to correctly manage the wide spectrum of thalassemia syndromes, biomarkers able to assess preventive and curative treatments in selected populations at increased risk of developing complications and to correctly evaluate interventional procedures in a homogeneous population are also needed. This Special Issue on “Emerging Therapies and Strategies in Thalassemia: Toward a New Era in Management” aims to update researchers and clinicians by highlighting the main points that could represent a remarkable therapeutic advancement or improvement in the management made recently in the field of thalassemia syndromes.

Guest Editors

Dr. Paolo Ricchi

Center for Rare Red Blood Cell Diseases, AORN A. Cardarelli, Naples, Italy

Dr. Raffaella Origa

SSD Talassemia, Ospedale Pediatrico Microcitemico Cao, Università di Cagliari, 09124 Cagliari, Italy

Deadline for manuscript submissions

closed (25 August 2025)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/189460

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/journal/

[jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).